INTRODUCTION:

HISTORY OF DPCO:

The Drugs Prices Control act 1966 replaced by 1970

The Drugs Prices Control Order replaced by of 1979

The Drugs Prices Control Order replaced by 1987

The Drugs Prices Control Order replaced by 1994

The Drugs Prices Control Order replaced by 1995

Finally, The Drugs Prices Control act 1995 was replaced by Drugs Prices Control act 2013

The Pharmacy education in our country has witnessed tremendous expansion in last one decade. However, the standard in education have been eroded by rising tides of mediocrity. There is an urgent need to initiate an academic exercise aimed at attaining revamping of curriculum, keeping in pace with current and emerging trends in the field of pharmacy.¹

DPCO, 1970:

A comprehensive order under Section 3 of the Essential Commodities Act was issued on May 16, 1970, and it replaced any earlier orders on the subject. The Drugs (Prices Control) Regulation, 1970 was the name given to this order. In its initial form, DPCO turned into a direct assault on a pharmaceutical company's ability to make a profit as well as an indirect attack on the cost of drugs. The government mandated that a corporation could no longer make more pre-tax profit from its pharmaceutical business than 15% of its pharmaceutical income (net of excise duty and income tax). Any additional revenue would need to be lodged with the authorities. Therefore, a pharmaceutical company was free to choose the prices it would charge for its goods. Product-smart margins have also been accommodating, provided that. At that time, the Indian pharmaceutical enterprise become in large part ruled with the aid of using MNC associates and subsidiaries. These MNCs have been hardly ever tormented by the fairly moderate shape of DPCO and continued running with inside the home market. However, FERA which got here in mid 70’s did lessen the operations of MNCs. Overall, the Indian pharma enterprise prospered from 1970 to the following DPCO 1979.²

DPCO, 1979:

The Drugs Prices Control Order of 1979 become issued on 31st March. In its revised version, the DPCO stipulated ceiling expenses for managed classes of bulk tablets and their formulations. In solving the price, the authorities endured to endorse the profitability ceiling and a top limit become placed on the go back on internet really well worth or capital hired for pharma companies. The retail expenses of managed formulations had been determined via way of means of making use of the idea of MAPE (Maximum Allowable Post Manufacturing Expenses). It becomes a mark-up on ex- manufacturing facility charges, supplied to cowl promoting and distribution charges together with retail and wholesale exchange margins.²

The pricing formulation become retail price = (MC+CC+PM+PC) x (1+MAPE/100) + excise duty, in which MC become the fabric fee together with fee of bulk tablets/excipients, CC become the conversion fee as per the dosage shape is, PM become the fee of packing fabric appropriate to dosage shape and PC become the packaging price labored out according with mounted costing procedures.²

The 1979 DPCO placed 370 tablets below rate control. These tablets have been segregated into 4 categories, having one-of-a-kind MAPE. See the desk below. The maximum essential tablets, along with life saving tablets have been installed Category I which had the least MAPE (Maximum Allowable Post-Manufacturing Expenses).²

Table 1: The Drugs Prices Control Order of 1979.²

Category	MAPE
1	40%
2	55%
3	100%
4	60%

DPCO, 1987:

The Drug Policy of 1986 and the Kelkar Committee Report served as the foundation for the promulgation of the DPCO, 1987, which took effect on August 26. The number of bulk tablets available for free manipulation in DPCO, 1987, fell from 370 to 142.²

Table 2: The Drugs Prices Control Order of 1987.²

Category	MAPE
1	75%
2	100%

The Drug Policy of 1994:

The brand new drug coverage was announced in September 1994. It is the drug policy of the authorities that sets the standards for deciding on bulk pills or formulations for charge management. The new drug policy liberalised those standards. In addition, business licencing was abolished for all bulk pills. All impediments to capability expansions had been removed, and it was predicted that as a result, supply would surge upward, resulting in higher aggressive pressures. Foreign funding in the amount of 51% turned out to be authorised in the case of all bulk pills, their intermediates, and formulations. FDI in excess of 51% is considered on a case-by-case basis. Nonetheless, until 1998, five bulk pills—Vitamin B1, Vitamin B2, Folic Acid, Tetracycline, and Oxytetracycline—were reserved for the general public.²

DPCO, 1995:

On January 6, 1995, the modern-day Drug Price Control Order was issued. The primary shape of this DPCO is similar to that of the earlier orders. Nevertheless, the span of charge management under DPCO 1995 has been significantly liberalized, going from 142 pills to simply seventy-six. The Pricing of Bulk Drugs The seventy-six bulk pills, the costs of which might be managed under DPCO 1995, were enlisted within the First Schedule annexed to the order.²

The method used by DPCO to maintain stable costs for bulk pills is as follows: The government must provide either a post-tax go-back of 14% on very worthwhile online purchases or a go-back of 22% on capital utilised when resolving the highest sale price of a bulk medicine.²

What is Drug Price Control Order, 2013:

The Department of Pharmaceuticals and the Ministry of Chemicals and Fertilizers introduced the Drugs Price Control Act, 2013, to increase the availability of straightforward drug treatments at affordable prices across the nation. The order was given by the Indian government in accordance with Section 3 of the Essential Commodities Act of 1955, which governs drug pricing in the nation. For the execution of DPCO 2013, the National Pharmaceutical Pricing Authority (NPPA) can be held responsible. It was provided in May 2013 and, mostly based on their production costs, had an impact on the pricing of over 348 crucial drug treatments. All dosages included on the National List of Essential Medicines (NLEM) may be under rate control, according to the DPCO 2013.³

1. What Is Drug Pricing:

Defination: This is a measure of the rate paid with the aid of using pharmacies to buy drug merchandise from wholesalers inside the supply chain.

The annual Indian pharmaceutical market is measured at rate of 20% and 79,000 Crore. India ranks 2^nd in top 6 pharmaceutical global producers. Indian vaccines are exported nearly to 150 other countries. 40-70 percent of the World Health Organization (WHO) demand for Diphtheria-Pertussis-Tetanus and BacilleCalmette-Guérin vaccine (DPT and BCG) and also 90% of measles vaccine is manufactured by India.⁴

India Retail is generating considerable interest within the country and abroad as it contributes 33% of the country’s fast growing GDP. Organized retail, best represented by the mushrooming OTC outlets, has come to play a defining role in building and supporting this veritable base of retail consumers. A good percentage of this retail growth is fueled by consumption of the youth in the country who constitute 54% of the population and number about 555 million.⁵ The term implies having a comprehensive knowledge of all of the factors that affect the business. It is imperative that firms have an in depth knowledge about factors such as the customers, competitors, business partners, economic environment, and internal operations to make effective and good quality business decisions.^6,7

2.1 Objectives:

i. To make certain availability of vital and life-saving, and prophylactic medicinal drug of top high-satisfactory at affordable prices.

ii. To offer of possibility for innovation and research-orientated drug manufacturing.

iii. Allow honest opposition to help the boom of the industry.

iv. To meet the dreams of employment and shared financial improvement of all.⁸

2.2 DPCO and Functions:

Drug rate regulation has caused the pharmaceutical business a great deal of pain. Price caps on capsules have the power to stifle industry growth and prevent the general public from having access to the newest lifestyle-saving capsules, even when they are based on a greater public hobby perspective. To the dismay of the main players and their business structures, it is an excellent offer. Of course, the government has followed the public's example, and the courts have also been a huge help in this regard.

Price manipulation, to a degree, has met its fair share of demanding situations and, as a coverage issue, is here to stay. Alternatively, the interpretation of fee manipulation regulations (DPCO) continues to be the subject of a great deal of contentious litigation in courts.⁸

2.3 NPPA ROLE:

· National Pharmaceutical Pricing Authority monitors the prices of decontrolled (non- scheduled) formulations on regular basis.

· The NPPA, which has been delegated the government's powers in this regard, believes that there are significant inter-brand price differences in branded-generics and off-patent drugs, indicating an excessive marketplace failure, as distinct brands of the same drug components, including off-patent drugs, that are the same in terms of active ingredient (s), strength, dosage, route of administration, quality, product characteris.

· Furthermore, although it has been found that the binders, fillers, colours, preservatives, coating agents, and dissolve agents used by the various producers of the drug formulation can occasionally vary, those changes aren't substantial in terms of the therapeutic effect.

· And while there are several reasons why the market in India has failed to recognise prescription pharmaceuticals, the most significant is that the demand for drug treatments is mostly driven by prescriptions, and the patient has little to no preference in this area.⁸

3. Main Features of DPCO 2013 Are:

· It brought 348 drugs and their 652 formulations under price control.

· The new policy uses a market-based pricing mechanism against the prior proposed cost-plus method.

· Margins of wholesalers and retailers have been cut down to 8% and 16%, respectively.

· To monitor the M.R.P. of non-schedule formulations.

· Control over bulk drug and formulation manufacturers.⁸

3.1 What is Ceiling price:

Means a price constant through the Government for Scheduled formulations in according with the provisions of paragraph 9.

Calculation of ceiling price of a scheduled formulation:

The ceiling price of a scheduled formulation of specified strengths and dosages as specified under the first schedule shall be calculated as under:

First Step: First the Average Price to Retailer of the scheduled formulation i.e. P(s) shall be calculated as below:

Average Price to Retailer,

P(s) = (Sum of prices to retailer of all the brands and generic versions of the medicine having market share more than or equal to one percent of the total market turnover on the basis of moving annual turnover of that medicine) / (Total number of such brands and generic versions of the medicine having market share more than or equal to one percent of total market turnover on the basis of moving annual turnover for that medicine.)

Second Step: Thereafter, the ceiling price of the scheduled formulation i.e. P(c) shall be calculated as below:

P(c) = P(s).(1+M/100)

Where, P(s) = Average Price to Retailer for the same strength and dosage of the medicine as calculated in step1 above.

M = % Margin to retailer and its value =16.⁹

3.2 Margins For Wholesaler And Retailer:

Global OTC pharmaceuticals grew with CAGR of 5.1% for the five year period spanning 2002- 06 to reach $88.7 billion. At a global level Parma giants are leveraging the power of OTC to face the challenges they face today .Globalization, shrinking new product pipeline, increasing cost of new drug discovery, shrinking PLC of existing products, ever increasing demand by managed healthcare organizations, public and government to cut down the prices of patent protected drugs, stringent safety rules of FDA and entry of new players in the market are putting tremendous pressure on all Parma companies especially the giants. Pfizer Inc’s, world’s largest drug maker, recent decision to cut US sales force by about 20% clearly express the pressure such giants face.¹⁰

In all but a few technology categories where growth prospects are strong, companies are in a battle for market share and, in some cases, survival. Knowing your cost structure can ensure that any cuts or consolidation initiatives will save the most money with minimum customer impact.^11,12

Margin to retailer: While fixing a ceiling rate of scheduled formulations and retail costs of recent drugs, 16 percentage of rate to retailer as a margin to retailer will be allowed.¹³

Maximum retail rate:

The most retail charge of scheduled formulations will be constant with the aid of using the producers on the foundation of ceiling rate notified with the aid of using the Government plus local taxes anyplace applicable, as under follow:¹³

Maximum Retail Price = Ceiling rate + Local Taxes as applicable⁷

The retail business in particular and the country India in general have, of late, captured the imaginations of the retail world. This sector has undergone significant changes and is fast emerging. India has become one of the most lucrative markets for international retailers.^14,15

4. Punishment for Violation:

What are the punishments for violating the DPCO, 2013? Depending on the seriousness of the offence, failure to comply with the rate notification given by the NPPA may lead to prosecution under the Essential Commodities Act (ECA), 1955. According to Section 7 of the ECA of 1955, the minimum sentence for imprisonment is three months, but it can be enhanced to seven years if the offence is particularly serious.

Section 9 of the ECA, 1955 makes fake statements/ information additionally punishable with imprisonment for a time period which can also additionally make bigger to 5 years.

Under phase 10 of the ECA, 1955, offences dedicated via way of means of agencies are punishable, and shall practice to everyone who, on the time the contravention become dedicated, become in rate of, and become accountable to, the agency for behavior of the enterprise of the agency in addition to the agency, will be deemed to be responsible of the contravention and will be prone to be proceeded in opposition to and punished accordingly. Every offence dedicated below the Essential Commodities Act, 1955 is a cognizable offence.¹⁶

4.1 Enforcement Aggecies:

· National Pharmaceutical Pricing Authority (NPPA),

· The FDA/ Drugs Controller of the State,

· Drugs Inspector (DI) of the District are the enforcing authorities at National / State/ District Levels.¹⁶

5. What Is Retail Price:

A retail rate is a rate at which a formulation/medicinal drug is bought to a consumer/user. The manufacturer of the formulation is needed to print this kind of rate at the label of the product. In case of managed formulations, the retail rate is the rate constant through the Government for a brand new drug below paragraph five of Drugs (Prices Control) Order, 2013.¹⁶

5.1 What is the essential/obligatory facts this is required to be imprinted on the label of the medication pack:

The following facts is needed to be imprinted on the label of a medicinal drug below the Drugs and Cosmetics Act and DPCO, 2013. Name of the components Composition of the components, Pack Size, Address of the producer, Manufacturing License Number, Date of manufacture, Expiry Date, Maximum Retail Price (which includes all taxes) etc.¹⁶

What is the overall quantity required to be paid for a medicinal drug:

The revealed MRP (Maximum Retail Price) is the most payable quantity. However, a medicinal drug may be bought under this rate.¹⁶

6. Why are the costs of drugs rising:

· The motives for upward thrust with inside the costs of drugs: upward thrust with inside the rate of bulk drugs;

· Upward thrust with inside the price of excipients used with inside the manufacturing of drugs like Lactose, Starch, sugar, glycerine, solvent, gelatine tablets etc.;

· Upward thrust with inside the value of transport, freight rates;

· Upward thrust with inside the fee of utilities like fuel, power, diesel, etc.; for imported drugs, upward thrust within side the c.i.f.(Cost, Insurance and freight) charge and depreciation of the Rupee; modifications in taxes and duties.¹⁶

7. Methodology for Price Fixation:

The ceiling price of a scheduled formulation of specified strengths and dosages as specified under the first schedule shall be calculated as under:

First the Average Price to Retailer of the scheduled formulation

The ceiling price of the scheduled formulation.

i.e. P(c) shall be calculated as below:

P(c) = P(s).(1+M/100)

Where,

P(s) = Average Price to Retailer for the same strength and dosage of the medicine as calculated in step 1 above;

M = % Margin to retailer and its value =16.¹⁶

8. Data Analysis:

Drug price control order: the impact on pharmacoeconomics:

Pharmacoeconomics has been defined as the description and assessment of the cost of a drug remedy to the health-care system and society. It identifies, measures, and compares the costs (assets consumed) and consequences (i.e., clinical, economic, and humanistic) of pharmaceutical merchandise and services. It is a critical tool for resource allocation and selection making in numerous pharmaceutical sectors, which include drug pricing. Drug rate control order (DPCO) 2013 objectives aim to make all vital and lifesaving drugs available to all at inexpensive costs through the instrumentality of rate control. Under the Defense of India Act of 1963, the first rate control order was issued. After that, a rate control order was issued below the Essential Commodities Act 1970 and has been revised in 1979, 1987, 1995, and 2013. DPCO 2013 has been issued with the aid of the Ministry of Chemicals and Fertilizers for fixing the ceiling costs of 348 drugs.

With the assistance of the unbiased National Pharmaceutical Pricing Authority (NPPA), this is covered in the 2011 National List of Essential Medicines. The National Pharmaceutical Pricing Policy (NPPP) is used to monitor and manage drug costs with the help of the NPPA.

Mark NPPP is dependent on three key concepts: drug essentiality, MBP, and control of formulationsations. MBP is calculated by including the common costs of all the manufacturers of a drug having at least a 1% marketplace proportion plus local taxes and a 16% retailer`s income margin. three Violations of the DPCO can result in a 45-day notice period to the manufacturer, during which time the drug rate must be modified and the overcharged quantity, plus interest and penalties, must be submitted to the government. 4 This study compares the costs of numerous branded formulations used most regularly in medical practice with their constant ceiling charges given within the DPCO 2013 and assesses the compliance of the DPCO in conjunction with the effect of it on Indian pharmacoeconomics.¹⁷

Figure 1: Percentage of drugs having higher prices than DPCO2013.¹⁷

UNDERSTANDING:

Many of the brand formulations have higher rate than the DPCO 2013 issued with the aid of using authorities of India. The clinicians prescribing those tablets need to be conscious of those emblem formulations costs to lessen the price of the drug remedy and increase patient compliance. Strict vigilance from the Government and extra recognition from prescribers and patients are required. Better recommendations for regulatory implementation of DPCO is needed.¹⁷

9. CONCLUSION:

A maximum retail price (MRP) is a manufacturer calculated price that is the highest price that can be charged for a product sold in India. The NPPA regularly publishes list of medicines and the maximum ceiling prices. NLEM forms the basis of deciding which medicines should come under price control via DPCO.

This Act is very much helpful for patient who take regular medicine so, they can afford medicine in minimum price. Due to that the patient compliance is achieve. According to the need of the drug the medicine should place in essential medicine list.

DPCO 1995 is a win – win situation for the manufacturers where government has no control over the fixation of prices of drugs, where the prices of the drugs are fixed by manufacturing cost mechanism. DPCO 2013 has over come this problem by involving government in fixing the prices by simple average market price mechanism, by which the most of the lifesaving drug prices are fixed by government, which is a win-win situation for manufacturer and patient. There is no doubt that the Indian customer will be the biggest beneficiary under the new drug pricing control order 2013 (DPCO 2013). The impact over the industry can be analysed on short and long term basis.

10. REFERENCE:

1. Merlin N. J. Pharmacy Careers - An Overview. Asian J. Res. Pharm. Sci. Jan.-Mar. 201;1(1): 01-03

2. DPCO ACT. The Decontrol of Drug Prices in India Implications for the Indian Pharma Industry. Available on https://ccs.in/internship_papers/2002/27.pdf

3. Byjus. Drug Price Control Orders (DPCO). Available on https://byjus.com/free-ias-prep/drug-price-control-order-2013/

4. Thalkari AB, Karwa PN, Gawli CS. A Review on Online Pharmacy: Views and Counterviews. Asian J. Pharm. Tech. 2018; 8 (2):108-111.

5. Kanthe R. Consumer Buying Behavior and Non-Prescriptive Drugs Shopping In Sangli. Asian J. Management. 2010; 1(2): 55-60.

6. Awasthi A. Business Intelligence: Concepts, Components, Techniques and Benefits. Asian J. Management. 2012;3(4): 196-203.

7. Srivastava A, Saket R, Yadav C. Decision Variables of Purchase Intention: A Multivariate Analysis of Promotional Tools. Asian J. Management. 2011;2(2): 51-56.

8. What are the features and objective of DPCO. Available on https://pharmacampus.in/pharma-marketing/dpco-features-and-objectives/

9. Government of India Ministry of Chemicals and Fertilizers. Department of Pharmaceuticals National Pharmaceuticals Pricing Authority New Delhi 10thJuly2014. available on http://www.dpco2013.com/files/data/newpricenotification2014/87101471676346

10. Khan Y, Gupta P, Goswami D, Bihari B, Verma V. A Review on Marketing of OTC Drugs. Asian J. Res. Pharm. Sci. 2013;3(2): 72-78.

11. Singh D. Marketing Challenges and Opportunities during Recession. Asian J. Management. 2010;1(1): 08-13.

12. Kumar R, Kandasamy C. Consumer Durable Industry in India -A Bird’s Eye View. Asian J. Management. 2010;1(2): 61-64.

13. The Drugs (Prices Control) Order.2013, (Notified by SO1221 (E) dated15.05.2013 and as amended up to vide SO 1192(E)dated 22-03-2016). available on https://www.nppaindia.nic.in/wpcontent/uploads/2018/12/DPCO2013_03082016.pdf

14. Bhattacharya PK. Booming Retail Sector: Destination India. Asian J. Management. 2010; 1(1): 14-21.

15. Moharana R, Pattanaik S. Retailing in Emerging Markets: Trends, Prospects and Challenges. Asian J. Management. 2017; 8(3): 479-482.

16. FAQs on drug pricing. Available on https://vikaspedia.in/health/nrhm/national-health-policies/faqs-on-drug-pricing

17. Shah S, Singh A, Vachhani P. Drug price control order: the impact on Pharmacoeconomics. International Journal of Basic and Clinical Pharmacology.2019;8(10): 2220-2223.

18. To Regulate or Not to Regulate: DPCO2013 and The Modi-Mundi Pharma Case. Available on, https://corporate.cyrilamarchandblogs.com/2018/08/regulate-not-regulate-dpco-2013-modi-mundi-pharma-case/

19. Government of India Ministry of Chemicals and Fertilizers. Department of Pharmaceuticals National Pharmaceutical Pricing Authority. New Delhi,13thNovember 2018. available on http://www.nppaindia.nic.in/wp-content/uploads/2018/08/NPPA-has-fixed-Ceiling-prices-of-orthopedic-implants-knee-replacements-under-para-19-of-Drugs-prices-control-order-DPCO-2013-1.pdf

20. Government of India Ministry of Chemicals and Fertilizers. National list of essential medicines. available on https://main.mohfw.gov.in/newshighlights-104

21. Government of India. The Drugs and Cosmetic Act and Rules, 1945. available onhttps://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdfdocuments/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf

22. A Comparision Between Old and Latest Systems In DPCO. available on https://www.researchgate.net/figure/Comparison-of-DPCO-1995-DPCO-2013_tbl1_263657518

23. Government of India. Drugs (prices control) policy 1995. available onhttp://nppaindia.nic.in/DPCO95.htm,

24. National Pharmaceutical Pricing Authority. Extraordinary, PartII, Section3, Sub-section (ii) dated15thMay2013. available on http://nppaindia.nic.in/index1.html,

25. Hamid A, Sehgal S, Jaithliya T, Gadhiya J, Noorani Z, Sharma G. Drug Price Control Orders (DPCO). European Journal of Biomedical and Pharmaceutical Sciences. 2018;5(5): 953-956.

Received on 08.12.2022 Modified on 28.01.2023

Asian J. Pharm. Res. 2023; 13(4):263-268.

DOI: 10.52711/2231-5691.2023.00048